A
Alan Ashworth
Researcher at University of California, San Francisco
Publications - 589
Citations - 82138
Alan Ashworth is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 134, co-authored 578 publications receiving 72089 citations. Previous affiliations of Alan Ashworth include Imperial College London & Papworth Hospital.
Papers
More filters
Journal ArticleDOI
Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor
Swethajit Biswas,Madeleine Wood,Abhijit Joshi,Nick Bown,Lisa Strain,Tommy Martinsson,James Campbell,Alan Ashworth,Amanda Swain +8 more
TL;DR: It is suggested that adult AT/RT may not be markedly dissimilar to other adult brain tumors where mutations in a range of genes, reflecting the functional specialization of different brain regions, but including SMARCB1 inactivation, may be required for its pathogenesis.
Journal ArticleDOI
Alternative splicing of the Drosophila PTEN gene.
Anna Smith,Alice Smith,Saif Alrubaie,Carmen Coehlo,Sally J. Leevers,Sally J. Leevers,Alan Ashworth +6 more
TL;DR: It is shown that the PTEN gene is conserved in the invertebrate Drosophila melanogaster and demonstrated that the gene undergoes alternative splicing.
Journal ArticleDOI
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
Vishal Kothari,Jonathan F. Goodwin,Shuang G. Zhao,Justin M. Drake,Yi Yin,S. Laura Chang,Joseph R. Evans,Kari Wilder-Romans,Kristina Gabbara,Emanuela Dylgjeri,Jonathan Chou,G. Sun,Scott A. Tomlins,Rohit Mehra,Kristen Hege,Ellen Filvaroff,Edward M. Schaeffer,R. Jeffrey Karnes,David A. Quigley,Dana E. Rathkopf,Housheng Hansen He,Housheng Hansen He,Corey Speers,Daniel E. Spratt,Luke A. Gilbert,Alan Ashworth,Arul M. Chinnaiyan,Ganesh V. Raj,Karen E. Knudsen,Felix Y. Feng +29 more
TL;DR: The data show that DNAPK drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer.
Journal ArticleDOI
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Marina Danilenko,Elaine Stamp,Deborah D. Stocken,A. Husain,Monique Zangarini,Amy Cranston,Robert Stones,Naomi Sinclair,Kirsty Hodgson,Susan A Bowett,David Roblin,Silvio Traversa,Ruth Plummer,Gareth J. Veal,James A. A. Langtry,Alan Ashworth,John Burn,Neil Rajan +17 more
TL;DR: In this study, pegcantratinib, 0.5% (wt/wt), applied once daily appeared to be well tolerated and to penetrate the tumor tissue; however, the low tumor drug concentrations demonstrated are likely to account for the lack of response.
Journal ArticleDOI
BRCA2 in meiosis: turning over a new leaf
TL;DR: Investigating BRCA2 in distantly related organisms is likely to help to elucidate how the dysfunction of this gene leads to tumourigenesis.